Zero Candida Begins Prototype Production of AI-Enabled Therapeutic Device ZC-001

Zero Candida Technologies, Inc. has completed the design freeze and started prototype production of its ZC-001 therapeutic device, announced in a press release. The company will produce 50 prototype units, expected to be completed by the first quarter of 2026.

The ZC-001 device integrates blue light therapy, targeted drug delivery, and wireless diagnostics to provide personalized treatment for Vulvo-Vaginal Candidiasis (VVC). The design freeze finalizes specifications for both the device and its SMART docking and charging case.

Key features include a docking system for automatic alignment and sterilization, wireless connectivity for encrypted data transfer, light indicators for user feedback, and medical-grade materials for comfort and biocompatibility. The device is designed for at-home use with real-time data transmission to enable physician monitoring and AI-driven analytics.

According to the company, the modular design of ZC-001 will support scalable manufacturing and potential adaptation for other gynecologic applications.